Targeting the epigenetic reader "BET" as a therapeutic strategy for cancer

Bioorg Chem. 2023 Nov:140:106833. doi: 10.1016/j.bioorg.2023.106833. Epub 2023 Sep 4.

Abstract

Bromodomain and extraterminal (BET) proteins have the ability to bind to acetylated lysine residues present in both histones and non-histone proteins. This binding is facilitated by the presence of tandem bromodomains. The regulatory role of BET proteins extends to chromatin dynamics, cellular processes, and disease progression. The BET family comprises of BRD 2, 3, 4 and BRDT. The BET proteins are a class of epigenetic readers that regulate the transcriptional activity of a multitude of genes that are involved in the pathogenesis of cancer. Thus, targeting BET proteins has been identified as a potentially efficacious approach for the treatment of cancer. BET inhibitors (BETis) are known to interfere with the binding of BET proteins to acetylated lysine residues of chromatin, thereby leading to the suppression of transcription of several genes, including oncogenic transcription factors. Here in this review, we focus on role of Bromodomain and extra C-terminal (BET) proteins in cancer progression. Furthermore, numerous small-molecule inhibitors with pan-BET activity have been documented, with certain compounds currently undergoing clinical assessment. However, it is apparent that the clinical effectiveness of the present BET inhibitors is restricted, prompting the exploration of novel technologies to enhance their clinical outcomes and mitigate undesired adverse effects. Thus, strategies like development of selective BET-BD1, & BD2 inhibitors, dual and acting BET are also presented in this review and attempts to cover the chemistry needed for proper establishment of designed molecules into BRD have been made. Moreover, the review attempts to summarize the details of research till date and proposes a space for future development of BET inhibitor with diminished side effects. It can be concluded that discovery of isoform selective BET inhibitors can be a way forward in order to develop BET inhibitors with negligible side effects.

Keywords: BRD; Bromodomain; Cancer; Dual Target BET inhibitors; Epigenetic; Pan BET inhibitors; Selective BD2 inhibitors.

Publication types

  • Review

MeSH terms

  • Bromodomain Containing Proteins*
  • Chromatin
  • Epigenesis, Genetic
  • Histones
  • Humans
  • Lysine*
  • Neoplasms* / drug therapy

Substances

  • Chromatin
  • Histones
  • Lysine
  • Bromodomain Containing Proteins